文献速递抗栓抗凝管理药物不良反应与药物警戒

房颤患者胃肠道大出血后重启口服抗凝:DOAC与华法林有效性和安全性比较

Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin.
PubMed 文献 · Pharmacotherapy · 2025-08-25

本研究基于商业医保数据库2010—2017年数据,纳入房颤患者因大出血住院后90天内重启口服抗凝者4389例,其中华法林3016例、DOAC 1373例。经加权分析,DOAC组后续大出血住院风险(HR 0.76,95%CI 0.60–0.96)和NACE复合终点风险(HR 0.83,95%CI 0.72–0.97)均低于华法林组,缺血性卒中/SE住院风险无显著差异。

要点

  • 房颤患者胃肠道大出血后90天内重启DOAC较华法林降低后续大出血住院风险。
  • DOAC组NACE复合终点(死亡、缺血性卒中/SE、大出血住院)风险亦低于华法林。
  • 两组缺血性卒中/SE住院风险无显著差异(HR 0.91,95%CI 0.53–1.55)。

核心结论

  • 房颤患者胃肠道大出血后90天内重启DOAC较华法林与更低的大出血住院和NACE风险相关。

研究设计与样本

  • 纳入因大出血住院且90天内重启DOAC或华法林的成人房颤患者共4389例。
  • 采用稳定化逆概率治疗加权平衡基线协变量。

主要发现

  • 重启DOAC者1373例(31.3%),重启华法林者3016例(68.7%)。
  • 出院至重启抗凝的中位时间为24天(四分位距10–47天)。
  • DOAC vs 华法林后续大出血住院加权HR为0.76(95%CI 0.60–0.96)。
  • 缺血性卒中/SE住院加权HR为0.91(95%CI 0.53–1.55)。
  • NACE加权HR为0.83(95%CI 0.72–0.97)。

临床怎么用

  • 房颤患者胃肠道大出血存活后90天内重启抗凝时,可优先考虑DOAC以降低再出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are sparse data to guide resumption of direct oral anticoagulants (DOACs) versus warfarin in patients with atrial fibrillation (AF) who survive a major gastrointestinal bleeding (GIB) event. OBJECTIVE: To compare the risk-benefit profile of restarting DOACs versus warfarin among patients with AF following hospitalization for major GIB. METHODS: Using claims submitted to a commercial health insurance database from January 2010 to December 2017, we identified adult patients with AF hospitalized for a major GIB while receiving oral anticoagulants. Eligible patients were required to have survived and restarted oral anticoagulation with DOACs or warfarin within 90 days following hospital discharge for major GIB. The outcomes of interest were subsequent hospitalization for major bleeding, hospitalization for ischemic stroke/systemic embolism (SE), all-cause mortality, and net adverse clinical effect (NACE), which was a composite of all-cause mortality, hospitalization for ischemic stroke/SE, and hospitalization for major bleeding. Stabilized inverse probability of treatment weighting was used to balance measured covariates. RESULTS: Overall, 4,389 patients resumed oral anticoagulation, with 3016 (68.7%) on warfarin and 1373 (31.3%) on DOACs, within 90 days of hospital discharge for major GIB. The median (interquartile range) time from hospital discharge for major GIB to resumption of oral anticoagulant was 24 (10, 47) days. The weighted hazards ratio (HR) among individuals that resumed DOACs versus warfarin after major GIB was 0.76 (95% confidence interval, CI: 0.60, 0.96) for subsequent hospitalization for major bleeding, 0.91 (95% CI: 0.53, 1.55) for subsequent hospitalization for ischemic stroke/SE, and 0.83 (95% CI: 0.72, 0.97) for NACE. CONCLUSIONS: Among patients with AF who survived and resumed oral anticoagulation within the first 90 days after hospitalization for a major GIB event, restarting oral anticoagulation treatment with DOACs was associated with a lower risk of subsequent hospitalization for major bleeding and the composite outcome of ischemic stroke, SE, all-cause mortality, and recurrent or incident major bleeding.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Lawal OD, Aronow HD, Shobayo F, et al. Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin. Pharmacotherapy. 2025. PMID: 40852894. doi:10.1002/phar.70055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。